A phase 1 trial shows denileukin diftitox administered before CAR-T therapy has a favorable safety profile and encouraging efficacy in high-risk DLBCL patients, with an 86% overall response rate and 77% one-year progression-free survival. The treatment demonstrated consistent regulatory T-cell depletion, supporting its immunomodulatory mechanism. Larger controlled studies are needed to confirm these preliminary findings.
Citius Pharmaceuticals reported $3.9 million in first revenue from LYMPHIR's December 2025 launch for cutaneous T-cell lymphoma, while subsidiary Citius Oncology announced positive Phase 1 data showing 86% response rate when LYMPHIR was administered prior to CAR-T therapy in high-risk lymphoma patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06074107 |
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05144841 |
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04607772 |
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) |
WITHDRAWN | PHASE1/PHASE2 |
| NCT04279938 |
A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL |
WITHDRAWN | PHASE1 |
| NCT04049825 |
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL |
COMPLETED | PHASE1 |
